| Summary of Condensed Balance Sheet | 
Condensed Balance Sheet (in thousands USD)  
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 
 | 
 | 
  | 
  | 
  | 
 | 
  | 
  | 
  | 
 
 | 
 | 
  | 
  | 
  | 
 | 
  | 
  | 
  | 
 
Investment in subsidiaries  | 
    | 
$  | 
261,012 | 
   | 
   | 
$  | 
300,055 | 
   | 
 
   | 
    | 
 | 
 | 
   | 
   | 
 | 
 | 
   | 
 
 | 
    | 
   | 
261,012 | 
   | 
   | 
   | 
300,055 | 
   | 
 
   | 
    | 
 | 
 | 
   | 
   | 
 | 
 | 
   | 
 
 | 
    | 
 | 
 | 
 | 
   | 
 | 
 | 
 | 
 
   | 
    | 
 | 
 | 
   | 
   | 
 | 
 | 
   | 
 
Liabilities, temporary equity and stockholders’ equity  | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
 
 | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
 
 | 
    | 
$  | 
286 | 
   | 
   | 
$  | 
15,944 | 
   | 
 
   | 
    | 
 | 
 | 
   | 
   | 
 | 
 | 
   | 
 
 | 
    | 
 | 
 | 
 | 
   | 
 | 
 | 
 | 
 
   | 
    | 
 | 
 | 
   | 
   | 
 | 
 | 
   | 
 
 | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
 
Series A Preferred Stock; par value $1,000 per share; none authorized, issued and outstanding at December 31, 2021; 7,765,229 shares authorized, and 7,756,158 shares issued and outstanding at December 31, 2020  | 
    | 
   | 
—    
 | 
   | 
   | 
   | 
77,562 | 
   | 
 
   | 
    | 
 | 
 | 
   | 
   | 
 | 
 | 
   | 
 
Series A-1 Preferred Stock; par value $1,000 per share; none authorized, issued and outstanding at December 31, 2021; 10,480,538 shares authorized, 7,862,107 shares issued and outstanding at December 31, 2020  | 
    | 
   | 
—    
 | 
   | 
   | 
   | 
78,621 | 
   | 
 
   | 
    | 
 | 
 | 
   | 
   | 
 | 
 | 
   | 
 
Series B Preferred Stock; par value $1,000 per share; none authorized, issued and outstanding at December 31, 2021; 9,090,975 shares authorized, 9,090,975 shares issued and outstanding at December 31, 2020  | 
    | 
   | 
—    
 | 
   | 
   | 
   | 
90,910 | 
   | 
 
   | 
    | 
 | 
 | 
   | 
   | 
 | 
 | 
   | 
 
Series C Convertible Preferred Stock; par value $1,000 per share; none authorized, issued and outstanding at December 31, 2021; 6,872,894 shares authorized, 2,566,186 shares issued and outstanding at December 31, 2020  | 
    | 
   | 
—    
 | 
   | 
   | 
   | 
16,802 | 
   | 
 
   | 
    | 
 | 
 | 
   | 
   | 
 | 
 | 
   | 
 
 | 
    | 
 | 
 | 
 | 
   | 
 | 
 | 
 | 
 
   | 
    | 
 | 
 | 
   | 
   | 
 | 
 | 
   | 
 
 | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
 
Common stock, voting; par value $0.0001 per share; 315,000,000 shares authorized, 72,027,743 shares issued and outstanding at December 31, 2021; 55,659,643 shares authorized, 30,281,520 shares issued and outstanding at December 31, 2020  | 
    | 
   | 
7 | 
   | 
   | 
   | 
3 | 
   | 
 
Additional  paid-in  capital  | 
    | 
   | 
401,688 | 
   | 
   | 
   | 
135,616 | 
   | 
 
Accumulated other comprehensive loss  | 
    | 
   | 
(3,331 | 
)   | 
   | 
   | 
(1,677 | 
)   | 
 
 | 
    | 
   | 
(137,638 | 
)   | 
   | 
   | 
(113,726 | 
)   | 
 
   | 
    | 
 | 
 | 
   | 
   | 
 | 
 | 
   | 
 
Total stockholders’ equity  | 
    | 
 | 
 | 
 | 
   | 
 | 
 | 
 | 
 
   | 
    | 
 | 
 | 
   | 
   | 
 | 
 | 
   | 
 
Total liabilities, temporary equity and stockholders’ equity  | 
    | 
 | 
 | 
 | 
   | 
 | 
 | 
 | 
 
   | 
    | 
 | 
 | 
   | 
   | 
 | 
 | 
   | 
 
  
 | 
| Summary of Condensed Statements of Loss and Comprehensive Loss | 
  Condensed Statements of Loss and Comprehensive Loss (in thousands USD)         
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 |   
|    | 
    | 
 | 
   | 
   | 
 | 
   | 
   | 
 | 
   |   
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 |   
 Equity in net loss of  unconsolidated  subsidiaries    | 
    | 
$  | 
(29,177 | 
)   | 
   | 
$  | 
(27,716 | 
)   | 
   | 
$  | 
(23,678 | 
)   |   
 Change in fair value of warrant liability    | 
    | 
   | 
(5,267 | 
)   | 
   | 
   | 
7,485 | 
   | 
   | 
   | 
(235 | 
)   |   
   | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   |   
|    | 
    | 
 | 
 | 
 | 
   | 
 | 
 | 
 | 
   | 
 | 
 | 
 |   
   | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   |   
|    | 
    | 
 | 
 | 
 | 
   | 
 | 
 | 
 | 
   | 
 | 
 | 
 |   
   | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   |   
 Other comprehensive loss:    | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   |   
 Foreign currency translation adjustment    | 
    | 
   | 
(1,654 | 
)   | 
   | 
   | 
2,116 | 
   | 
   | 
   | 
517 | 
   |   
   | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   |   
|    | 
    | 
 | 
 | 
 | 
   | 
 | 
 | 
 | 
   | 
 | 
 | 
 |   
   | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   |                                   
 | 
| Summary of Condensed Statements of Cash Flows | 
   Condensed Statements of Cash Flows (in thousands USD)   
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 |   
|    | 
    | 
 | 
   | 
   | 
 | 
   | 
   | 
 | 
   |   
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 |   
 Cash flows from operating activities    | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 | 
 |   
|    | 
    | 
$  | 
(23,910 | 
)   | 
   | 
$  | 
(35,201 | 
)   | 
   | 
$  | 
(23,443 | 
)   |   
 Adjustments to reconcile net loss to net cash provided by operating activities    | 
    | 
   | 
   | 
   | 
   | 
   | 
—    | 
   | 
   | 
   | 
—    | 
   |   
 Equity in net loss of unconsolidated subsidiaries    | 
    | 
   | 
29,177 | 
   | 
   | 
   | 
27,716 | 
   | 
   | 
   | 
23,678 | 
   |   
 Change in fair value of warrant liability    | 
    | 
   | 
(5,267 | 
)   | 
   | 
   | 
7,485 | 
   | 
   | 
   | 
(235 | 
)   |   
   | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   |   
 Cash provided by operating activities    | 
    | 
 | 
 | 
 | 
   | 
 | 
 | 
 | 
   | 
 | 
 | 
 |   
   | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   |   
 Cash flows from investing activities    | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   |   
 Distribution from subsidiary    | 
    | 
   | 
5,947 | 
   | 
   | 
   | 
200 | 
   | 
   | 
   | 
80 | 
   |   
   | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   |   
 Cash provided by investing activities    | 
    | 
 | 
 | 
 | 
   | 
 | 
 | 
 | 
   | 
 | 
 | 
 |   
 Cash flows from financing activities    | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   |   
 Repurchase of common stock    | 
    | 
   | 
—    
 | 
   | 
   | 
   | 
(200 | 
)   | 
   | 
   | 
(80 | 
)   |   
 Issuance of common stock, net of transaction costs    | 
    | 
   | 
223,968 | 
   | 
   | 
   | 
—    | 
   | 
   | 
   | 
—    | 
   |   
 Settlement of preferred stock    | 
    | 
   | 
(229,915 | 
)   | 
   | 
   | 
—    | 
   | 
   | 
   | 
—    | 
   |   
   | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   |   
 Cash used in financing activities    | 
    | 
 | 
 | 
 | 
   | 
 | 
 | 
 | 
   | 
 | 
 | 
 |   
 Effect of exchange rate change on cash and cash equivalents    | 
    | 
 | 
 | 
 | 
   | 
 | 
 | 
 | 
   | 
 | 
 | 
 |   
   | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   |   
 Change in cash and cash equivalents and restricted cash    | 
    | 
 | 
 | 
 | 
   | 
 | 
 | 
 | 
   | 
 | 
 | 
 |   
 Cash and cash equivalents and restricted cash, beginning of   year    | 
    | 
 | 
 | 
 | 
   | 
 | 
 | 
 | 
   | 
 | 
 | 
 |   
   | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   |   
 Cash and cash equivalents and restricted cash, end of year    | 
    | 
 | 
 | 
 | 
   | 
 | 
 | 
 | 
   | 
 | 
 | 
 |   
   | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   |   
 
Non-cash  investing and financing activities:     | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   |   
 Equity issued for acquisition of Integron, LLC    | 
    | 
$  | 
—    
 | 
   | 
   | 
$  | 
—    
 | 
   | 
   | 
$  | 
7,000 | 
   |   
   | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   |   
 Share-based payment awards issued to employees of subsidiaries    | 
    | 
$  | 
1,839 | 
   | 
   | 
$  | 
1,161 | 
   | 
   | 
$  | 
1,682 | 
   |   
   | 
    | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   | 
   |                                            
 |